

## Treanda, Bendeka, Belrapzo

## **Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info: 🗆 Same as Requesting	Provider
Name:	NPI#:
Fax:	Phone:
Rendering Provider Info:  Same as Referring l	Provider 🗆 Same as Requesting Provider
Name:	NPI#:
Fax:	Phone:
	limits in accordance with FDA-approved labeling, d/or evidence-based practice guidelines.
Patient Weight:	ka
	_^S
Patient Height:	

<u>Cri</u> 1.	teria Questions:  What drug is being prescribed? □ Treanda □ Bendeka □ Belrapzo □ Other		
2.	What is the diagnosis?  Follicular lymphoma Chronic lymphocytic leukemia (CLL) without chromosome 17p deletion or without TP53 mutation Small lymphocytic lymphoma (SLL) without chromosome 17p deletion or without TP53 mutation Diffuse large B-cell lymphoma (DLBCL) Adult T-cell leukemia/lymphoma (ATLL) AIDS-related B-cell lymphoma (MCL) Marginal zone lymphoma (nodal, gastric MALT, non-gastric MALT, splenic) Mantle cell lymphoma (MCL) Mycosis Fungoides (MF) Sezary syndrome (SS) Peripheral T-cell Lymphoma (PTCL) Cutaneous anaplastic large cell lymphoma (ALCL) Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma Multiple myeloma Classical Hodgkin lymphoma Post-transplant lymphoproliferative disorders Histologic transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma without translocations of MYC and BCL2 and/or BCL6 High grade B-cell lymphoma Hepatosplenic gamma-delta T-Cell lymphoma Other		
3.	What is the ICD-10 code?		
4.	Is this a request for continuation of therapy with the requested drug? $\square$ Yes $\square$ No If No, skip to #6		
5.	Is there evidence of unacceptable toxicity or disease progression on the current regimen? $\square$ Yes $\square$ No No further questions		
б.	What is the requested regimen? Indicate ALL that apply.  The requested drug will be used as a single agent The requested drug will be used as subsequent therapy The requested drug will be used as palliative therapy The requested drug will be used in combination with rituximab The requested drug will be used in combination with obinutuzumab (Gazyva) The requested drug will be used in combination with lenalidomide (Revlimid) and dexamethasone The requested drug will be used in combination with bortezomib (Velcade) and dexamethasone The requested drug will be used in combination with brentuximab vedotin (Adcetris) The requested drug will be used in combination with gemcitabine and vinorelbine The requested drug will be used in combination with polatuzumab vedotin-piiq (Polivy) The requested drug will be used in combination with polatuzumab vedotin-piiq (Polivy) and rituximab The requested drug will be used as a component of RBAC500 (rituximab, bendamustine, and cytarabine) None of the above		
Coi	mplete the following section based on the patient's diagnosis, if applicable.		
<u>Sec</u> 7.	ection A: Diffuse Large B-Cell Lymphoma (DLBCL)  How many prior therapies has the patient received? therapies		
8.	Is the patient a candidate for transplant? ☐ Yes ☐ No		

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720 Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Treanda Bendeka, Belrapzo SGM -10/2020.

CVS Caremark Specialty Pharmacy

• 2211 Sanders Road NBT-6

• Northbrook, IL 60062

Phone: 1-888-877-0518

• Fax: 1-855-330-1720

• www.caremark.com

Prescriber or Authorized Signature	Date (mm/dd/yy)
X	
information is available for review if requested by CVS Ca	
I attest that this information is accurate and true, and tha	t documentation supporting this
12. Is the disease relapsed or progressive? ☐ Yes ☐ No	
Section E: Multiple Myeloma	
11. Is the disease: ☐ Relapsed ☐ Refractory ☐ None of the above	от ператоѕрієніє Фаніна-Вена 1-Сен Еутірнона
10. How many previous lines of chemoimmunotherapy has the p Section D: Cutaneous Anaplastic Large Cell Lymphoma (ALCL)	
<u>Histologic Transformation of Follicular Lymphoma to Diffuse La</u> and BCL2 and/or BCL6	
Section C: Histologic Transformation of Nodal Marginal Zone L	
Section B: High-Grade B-Cell Lymphoma, AIDS-Related B-Cell 9. Is the patient a candidate for transplant? ☐ Yes ☐ No	<u>Lymphoma</u>
	T 1